Age | Acute Myelocytic Leukemia Post Remission First | Relapse First | Relapse Following | Disease remission second | Disease remission Greater Than second | Primary Induction Failure | MYELODYSPLASTIC SYNDROME International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes | Leukemia, Myeloid, Accelerated Phase | imatinib | Blast Crisis
Item
1. patients with age </= 70 years with one of of the following: acute myeloid leukemia past first remission, in first or subsequent relapse, in second or greater remission or primary induction failure; myelodysplastic syndromes with intermediate or high risk ipss score; cml which has progressed to accelerated phase or blast crisis despite imatinib treatment
boolean
C0001779 (UMLS CUI [1])
C0023467 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0544452 (UMLS CUI [2,3])
C0205435 (UMLS CUI [2,4])
C0035020 (UMLS CUI [3,1])
C0205435 (UMLS CUI [3,2])
C0035020 (UMLS CUI [4,1])
C0332282 (UMLS CUI [4,2])
C0544452 (UMLS CUI [5,1])
C0205436 (UMLS CUI [5,2])
C0544452 (UMLS CUI [6,1])
C0439093 (UMLS CUI [6,2])
C0205436 (UMLS CUI [6,3])
C2347677 (UMLS CUI [7])
C3463824 (UMLS CUI [8,1])
C2827405 (UMLS CUI [8,2])
C0023472 (UMLS CUI [9])
C0935989 (UMLS CUI [10])
C0005699 (UMLS CUI [11])
Donor Relative HLA Matched | Unrelated Donors HLA Matched | HLA-A Antigens | HLA-B Antigens | HLA-C Antigens | HLA-DR Antigens | Allogeneic transplantation Hematopoietic progenitor cell Peripheral blood | Blood Donation Willing | Mismatch HLA-DQ Antigens Adverse effects Absent
Item
2. patients must have an hla matched (hla a, b, c, dr) related or unrelated donor willing to donate for allogeneic peripheral blood progenitor cell transplantation. (recent large analyses of the national marrow donor program indicate that a mis-match at the dq locus has no adverse effect on outcome. the current national standard of care is to consider only these 4 loci in identifying suitably "matched" donors.)
boolean
C0013018 (UMLS CUI [1,1])
C0080103 (UMLS CUI [1,2])
C1548978 (UMLS CUI [1,3])
C3179133 (UMLS CUI [2,1])
C1548978 (UMLS CUI [2,2])
C0019728 (UMLS CUI [3])
C0019737 (UMLS CUI [4])
C0019751 (UMLS CUI [5])
C0019764 (UMLS CUI [6])
C3511527 (UMLS CUI [7,1])
C0229664 (UMLS CUI [7,2])
C0005794 (UMLS CUI [8,1])
C0600109 (UMLS CUI [8,2])
C1881865 (UMLS CUI [9,1])
C0019761 (UMLS CUI [9,2])
C0879626 (UMLS CUI [9,3])
C0332197 (UMLS CUI [9,4])
Relative Haploidentical | KIR Genes | Recipient incompatible HLA-C Antigens | Recipient incompatible HLA-Bw antigen
Item
3. patients must have a haploidentical relative who is predicted to be alloreactive based upon the presence of the relevant kir genes and incompatibility with the recipient for hla c and bw antigens.
boolean
C0080103 (UMLS CUI [1,1])
C3829897 (UMLS CUI [1,2])
C0665952 (UMLS CUI [2,1])
C0017337 (UMLS CUI [2,2])
C1709854 (UMLS CUI [3,1])
C0427679 (UMLS CUI [3,2])
C0019751 (UMLS CUI [3,3])
C1709854 (UMLS CUI [4,1])
C0427679 (UMLS CUI [4,2])
C0312673 (UMLS CUI [4,3])
Zubrod Performance Status
Item
4. zubrod performance status </= 2.
boolean
C3714786 (UMLS CUI [1])
Left ventricular ejection fraction | Cardiac Arrhythmia Uncontrolled | Heart Disease Symptomatic Uncontrolled
Item
5. left ventricular ejection fraction >/= 45%. no uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease.
boolean
C0428772 (UMLS CUI [1])
C0003811 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0018799 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0205318 (UMLS CUI [3,3])
Lung disease Symptomatic | FEV1 | Forced vital capacity | Carbon Monoxide Diffusing Capability Test | Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide
Item
6. no symptomatic pulmonary disease. forced expiratory volume at one second (fev1), forced vital capacity (fvc) and diffusing capacity of lung for carbon monoxide (dlco) >/= 50% of expected, corrected for hemoglobin.
boolean
C0024115 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0748133 (UMLS CUI [2])
C1287681 (UMLS CUI [3])
C1516251 (UMLS CUI [4])
C4054790 (UMLS CUI [5])
Creatinine measurement, serum
Item
7. serum creatinine </= 1.8mg%.
boolean
C0201976 (UMLS CUI [1])
Alanine aminotransferase measurement | Alanine aminotransferase measurement Malignant Neoplasms Related
Item
8. serum glutamate pyruvate transaminase (sgpt) </= 200 iu/ml unless related to patients malignancy.
boolean
C0201836 (UMLS CUI [1])
C0201836 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
Serum total bilirubin measurement
Item
9. bilirubin </= 1.5 mg/dl (unless gilbert's syndrome).no evidence of chronic active hepatitis or cirrhosis. if positive hepatitis serology, discuss with study chairman and consider liver biopsy.
boolean
C1278039 (UMLS CUI [1])
Informed Consent | Informed Consent Patient Representatives | Informed Consent parent | Informed Consent Guardian
Item
10. patient or patient's legal representative, parent(s) or guardian able to sign informed consent.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
C0021430 (UMLS CUI [3,1])
C0030551 (UMLS CUI [3,2])
C0021430 (UMLS CUI [4,1])
C1274041 (UMLS CUI [4,2])
Hypersensitivity mouse protein | Hypersensitivity Monoclonal Antibodies
Item
11. no known allergy to mouse proteins or monoclonal antibodies
boolean
C0020517 (UMLS CUI [1,1])
C1334805 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0003250 (UMLS CUI [2,2])
Communicable Disease Uncontrolled | Antimicrobial medicament | Absent response to treatment
Item
1. uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. the protocol pi is the final arbiter of eligibility.
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0443071 (UMLS CUI [2])
C0438286 (UMLS CUI [3])
Pleural effusion | Pericardial effusion | Ascites
Item
2. pleural/pericardial effusion or ascites estimated to be >1l.
boolean
C0032227 (UMLS CUI [1])
C0031039 (UMLS CUI [2])
C0003962 (UMLS CUI [3])
HIV Seropositivity
Item
3. hiv-positive.
boolean
C0019699 (UMLS CUI [1])
Pregnancy | Childbearing Potential Beta HCG positive | Postmenopausal state Duration | Female Sterilization
Item
4. pregnancy: positive beta human chorionic gonadotropin (hcg) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
boolean
C0032961 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C0813152 (UMLS CUI [2,2])
C0232970 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
C0015787 (UMLS CUI [4])
Hypersensitivity mouse protein
Item
5. known allergy to mouse proteins.
boolean
C0020517 (UMLS CUI [1,1])
C1334805 (UMLS CUI [1,2])
Antineoplastic Agents Systemic | Mylotarg | Chemotherapy | Toxicity Unresolved CTCAE Grades | hydroxyurea | Ara-C Low dose | Induction Therapy Refractory | intrathecal chemotherapy | Maintenance therapy Lumbar microdiscectomy Remission
Item
6. patient has received other systemic chemotherapeutic drugs (including mylotarg) within 14 days prior to trial enrollment or has unresolved grade >1 toxicity from prior chemotherapy treatment. (hydroxyurea or low dose ara-c less than or equal to 20 mg/m2/d is permitted if indicated to control induction refractory disease, and it chemotherapy is allowed if indicated as maintenance treatment for previously diagnosed lumbar microdiscectomy (lmd), that is in remission prior to enrollment on this study).
boolean
C0003392 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0876099 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0600688 (UMLS CUI [4,1])
C0443342 (UMLS CUI [4,2])
C1516728 (UMLS CUI [4,3])
C0020402 (UMLS CUI [5])
C0733521 (UMLS CUI [6,1])
C0445550 (UMLS CUI [6,2])
C0600558 (UMLS CUI [7,1])
C0205269 (UMLS CUI [7,2])
C1517560 (UMLS CUI [8])
C0677908 (UMLS CUI [9,1])
C0457629 (UMLS CUI [9,2])
C0544452 (UMLS CUI [9,3])